Traders should monitor the March 9 webcast for interim efficacy and safety signals from the Phase 3 trial; positive data could catalyze significant upside given the high unmet need in CIDP and DNTH's $2.8B market cap.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 9 $79.23entry
- T+1 · 8mo ago +9.71%α +9.89% · $86.92
- T+5 · 8mo ago −1.55%α −0.20% · $78.00
- T+20 · 7mo ago +8.80%α +11.60% · $86.20
- T+60 · 6mo ago +2.95%α −9.03% · $81.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dianthus Therapeutics announced a conference call to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP, scheduled for March 9, 2026. The event is material as it pertains to a key clinical milestone for a Phase 3 program in a severe autoimmune disease, but no results have been disclosed yet.
Key Facts
- Company to discuss interim responder analysis from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.
- Data discussion scheduled for March 9, 2026, at 8:00 a.m. ET via webcast and conference call.
- No clinical results are released in this announcement, only logistical details for an upcoming event.
- Claseprubart is being evaluated for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare and severe autoimmune neurological disorder.
Financial Impact
Potential high impact pending data release, but no financial figures disclosed in this announcement.
Risk Factors
- Interim data may show suboptimal response rates or safety concerns, leading to downside risk.
- Responder analysis is not a primary endpoint and may not predict final trial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251470 |
Track record
23 reports on DNTH
7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers